Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory P Geba

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
The Clinical Journal of Pain|April 9, 2005
The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trialsPaul J Desjardins, Donald R Mehlisch, David J Chang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 18, 2019
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical TrialPaula Dakin, Stephen J DiMartino, Haitao Gao, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 18, 2006
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetoneArthur L Weaver, Ronald P Messner, William W Storms, et al.
Osteoarthritis and Cartilage|July 14, 2024
Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imagingStephen J DiMartino, Haitao Gao, Tuhina Neogi, et al.
The European Respiratory Journal|June 30, 2012
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEdward Piper, Christopher Brightling, Robert Niven, et al.
BMJ Open|January 17, 2024
Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily livesDiana Rofail, Selin Somersan-Karakaya, Julia Y Choi, et al.
Journal of Patient-Reported Outcomes|August 8, 2024
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrumentDiana Rofail, Selin Somersan-Karakaya, Eleftherios Mylonakis, et al.
Annals of Internal Medicine|October 8, 2003
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trialJeffrey R Lisse, Monica Perlman, Gunnar Johansson, et al.
RMD Open|January 16, 2026
A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hipStephen J DiMartino, Helen Cicirello, Andrew Magyar, et al.
Annals of the Rheumatic Diseases|November 17, 2020
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trialPaula Dakin, Alan J Kivitz, Joseph S Gimbel, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
The Clinical Journal of Pain|April 9, 2005
The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trialsPaul J Desjardins, Donald R Mehlisch, David J Chang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 18, 2019
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical TrialPaula Dakin, Stephen J DiMartino, Haitao Gao, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 18, 2006
Treatment of patients with osteoarthritis with rofecoxib compared with nabumetoneArthur L Weaver, Ronald P Messner, William W Storms, et al.
Osteoarthritis and Cartilage|July 14, 2024
Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imagingStephen J DiMartino, Haitao Gao, Tuhina Neogi, et al.
The European Respiratory Journal|June 30, 2012
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEdward Piper, Christopher Brightling, Robert Niven, et al.
BMJ Open|January 17, 2024
Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily livesDiana Rofail, Selin Somersan-Karakaya, Julia Y Choi, et al.
Journal of Patient-Reported Outcomes|August 8, 2024
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrumentDiana Rofail, Selin Somersan-Karakaya, Eleftherios Mylonakis, et al.
Annals of Internal Medicine|October 8, 2003
Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trialJeffrey R Lisse, Monica Perlman, Gunnar Johansson, et al.
RMD Open|January 16, 2026
A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hipStephen J DiMartino, Helen Cicirello, Andrew Magyar, et al.
Annals of the Rheumatic Diseases|November 17, 2020
Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trialPaula Dakin, Alan J Kivitz, Joseph S Gimbel, et al.
Pageof 7